DRTS: Bullish Pennant detected on 26 Feb 2026

DRTS is forming a bullish pennant following a 120% three-month rally, with the stock trading at $8.42 near recent highs and testing resistance at $8.60. The pattern exhibits strong structure (12.5/15), solid volume confirmation (12.0/12 with 2.74x relative volume), and solid breakout dynamics (11.7/13). The overall score of 85.2 reflects a high-conviction technical setup, further supported by a 76.39% win probability. Current consolidation sits just 2.09% below the 52-week high of $8.60, positioning this as a potential breakout into new territory. Volume is 2.74x average, signaling conviction behind recent price action.

Alpha Tau received Japan's Shonin marketing approval on Feb 24, 2026, for Alpha DaRT to treat unresectable locally advanced or locally recurrent head and neck cancer—marking the company's first regulatory clearance outside Israel. The FDA modular PMA submission occurred on Jan 5, 2026, using an ongoing review approach. Final pancreatic cancer results presented at ASCO GI 2026 showed a 22% objective response rate and 81% disease control rate across 32 patients. Five concurrent U.S. clinical trials are running with targeted patient-accrual milestones and planned data readouts expected across pancreatic cancer, glioblastoma, and recurrent cutaneous squamous cell carcinoma throughout 2026. ARK Invest added Alpha Tau to its ARK Israel Innovative Technology ETF in January 2026, signaling institutional recognition. The Health Care sector is in a bullish regime (0.95 score), providing tailwinds for biotech advancement announcements.

A successful pennant breakout would target $8.97 based on the conservative measured move, requiring volume confirmation above current 932,328 share levels to validate the move through resistance at $8.60. Historical data shows a 76.39% win probability for this pattern type and setup quality. The pattern invalidates below support at $6.59—roughly 22% downside from current levels. Volume surge above 340,749 (20-day average) would accelerate the breakout trajectory. A confirmed close above $8.60 coupled with sustained elevated volume would signal momentum continuation toward the target and potentially beyond, given the bullish technical framework underlying the breakout structure.

Alpha Tau reported a net loss of $11.7 million in Q3 2025, indicating substantial ongoing cash burn typical of early-stage oncology companies. The company faces material risks from potential clinical trial failures, inability to secure U.S. regulatory approval, and competition in market adoption. Fundamentals remain weak with no revenue, ongoing losses, and persistent cash burn; additionally, overbought momentum indicators add downside risk. The RSI at 67.66 approaches overbought territory (>70), signaling potential pullback risk. The Japan approval announcement on Feb 24 generated only a -0.14% price reaction, indicating market indifference to near-term non-U.S. catalysts. U.S. data readouts (pancreatic, GBM) expected by late 2026 represent both upside catalysts and execution risks, with failure or disappointing results capable of reversing recent gains significantly.